MissionIR Exclusive Audio Interview With Actinium Pharmaceuticals CEO Dr. Kaushik J. Dave
MissionIR Exclusive Audio Interview With Actinium Pharmaceuticals CEO Dr. Kaushik J. Dave
ATLANTA, GA--(Marketwired - Jan 30, 2014) - MissionIR today announces the online availability of its interview with Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) president and Chief Executive Officer Dr. Kaushik J. Dave, a 25-year veteran with extensive biotech and pharmaceutical experience. The full audio interview is available at the following link: http://ATNM.MissionIR.com/interview.html.
Actinium is a biotech company leveraging modern science and its proprietary platform to develop and commercialize groundbreaking therapies for treatment in different types of cancer that currently do not have any approved treatment.
Iomab-B is the company's lead program for bone marrow conditioning in patients with acute myeloid leukemia (AML) who do not have any curative treatment options. Iomab-B is poised to start a pivotal phase 3 study, backed by significant data from five completed phase 1 and phase 2 clinical trials.
"This program has the potential to disrupt the field of bone marrow transplant, and as a consequence, has attracted a significant amount of interest from the medical community," Dr. Dave stated in the interview.
Actinium's pipeline also includes Actimab-A, currently in phase 1/phase 2 clinical studies as a primary induction treatment of AML. The company's business model is to leverage its expertise and strong partnerships with leading cancer institutions to further the development of these drug candidates.
Dr. Dave detailed his education and extensive background in the pharmaceutical industry and drug development, noting that his interest in joining Actinium stemmed from recognizing the company's "significant unrealized potential for growth." Dr. Dave also briefly touched on the blended expertise of the rest of Actinium's leadership and board of directors.
"These folks, all of them, bring complementary skills... all of which make our team well-equipped to face challenges of a rapidly ascending biotech company," he stated.
In 2013, Actinium achieved several important milestones, as explained by Dr. Dave in the interview, which have positioned the company to reach several key objectives in 2014, including:
Iomab-B poised to start phase 3
Interim phase 2 results for Actimab-A
Uplist to Nasdaq or NYSE exchange
Obtaining additional analyst coverage
Establish strategic collaborations
Wrapping up the interview, Dr. Dave explained Actinium position in the biotech industry, how it is raising awareness in the investment community, and the company's recent private placement of approximately $6.6 million in gross proceeds, which is allocated toward achieving the company goals for the year.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
For additional information, please visit the Company's corporate Website: www.ActiniumPharmaceuticals.com
This press release may contain "forward-looking statements." Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.
Actinium Pharmaceuticals
New York, NY
www.ActiniumPharmaceuticals.com
646-459-4201
CSohmer@ActiniumPharmaceuticals.com
Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com
MissionIR Exclusive Audio Interview With Actinium Pharmaceuticals CEO Dr. Kaushik J. Dave
ATLANTA, GA--(Marketwired - Jan 30, 2014) - MissionIR today announces the online availability of its interview with Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) president and Chief Executive Officer Dr. Kaushik J. Dave, a 25-year veteran with extensive biotech and pharmaceutical experience. The full audio interview is available at the following link: http://ATNM.MissionIR.com/interview.html.
Actinium is a biotech company leveraging modern science and its proprietary platform to develop and commercialize groundbreaking therapies for treatment in different types of cancer that currently do not have any approved treatment.
Iomab-B is the company's lead program for bone marrow conditioning in patients with acute myeloid leukemia (AML) who do not have any curative treatment options. Iomab-B is poised to start a pivotal phase 3 study, backed by significant data from five completed phase 1 and phase 2 clinical trials.
"This program has the potential to disrupt the field of bone marrow transplant, and as a consequence, has attracted a significant amount of interest from the medical community," Dr. Dave stated in the interview.
Actinium's pipeline also includes Actimab-A, currently in phase 1/phase 2 clinical studies as a primary induction treatment of AML. The company's business model is to leverage its expertise and strong partnerships with leading cancer institutions to further the development of these drug candidates.
Dr. Dave detailed his education and extensive background in the pharmaceutical industry and drug development, noting that his interest in joining Actinium stemmed from recognizing the company's "significant unrealized potential for growth." Dr. Dave also briefly touched on the blended expertise of the rest of Actinium's leadership and board of directors.
"These folks, all of them, bring complementary skills... all of which make our team well-equipped to face challenges of a rapidly ascending biotech company," he stated.
In 2013, Actinium achieved several important milestones, as explained by Dr. Dave in the interview, which have positioned the company to reach several key objectives in 2014, including:
Iomab-B poised to start phase 3
Interim phase 2 results for Actimab-A
Uplist to Nasdaq or NYSE exchange
Obtaining additional analyst coverage
Establish strategic collaborations
Wrapping up the interview, Dr. Dave explained Actinium position in the biotech industry, how it is raising awareness in the investment community, and the company's recent private placement of approximately $6.6 million in gross proceeds, which is allocated toward achieving the company goals for the year.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
For additional information, please visit the Company's corporate Website: www.ActiniumPharmaceuticals.com
This press release may contain "forward-looking statements." Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.
Actinium Pharmaceuticals
New York, NY
www.ActiniumPharmaceuticals.com
646-459-4201
CSohmer@ActiniumPharmaceuticals.com
Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com
